Unnamed: 0,title,date,stock,sentiment
1307678.0,Veracyte Announces De Novo Classification Request To FDA For nCounter Dx LymphMark Assay,2020-06-09 08:18:00-04:00,VCYT,negative
1307679.0,UPDATE: CareDx Will Become Exclusive Worldwide Commercialization Partner For Solid Organ Transplant-rejection Tests On Veracyte's Diagnostic Platform,2020-05-14 08:18:00-04:00,VCYT,positive
1307680.0,CareDx And Veracyte Announce Exclusive Partnership For Transplant Rejection Testing On nCounter System,2020-05-14 08:17:00-04:00,VCYT,negative
1307681.0,"SVB Leerink Maintains Outperform on Veracyte, Raises Price Target to $32",2020-05-07 07:05:00-04:00,VCYT,neutral
1307682.0,"Veracyte Q1 EPS $(0.240) Misses $(0.200) Estimate, Sales $31.122M Beat $30.600M Estimate",2020-05-06 16:15:00-04:00,VCYT,negative
1307683.0,"The Daily Biotech Pulse: FDA Nod For AstraZeneca, AbbVie-Allergan Deal Clears Antitrust Hurdle",2020-05-06 08:42:00-04:00,VCYT,positive
1307684.0,The Week Ahead In Biotech: Smid-Cap Earnings News Flow Picks Up Pace,2020-05-03 08:45:00-04:00,VCYT,neutral
1307685.0,"Veracyte, Yale Report Exclusive License Deal To Advance First Genomic Monitoring Testing For Idiopathic Pulmonary Fibrosis, No Terms Disclosed",2020-04-23 08:16:00-04:00,VCYT,negative
1307686.0,"Shares of several healthcare companies are trading lower with the overall market on continued downward momentum after oil prices fell to historic lows, partially stemming from weak demand caused by the coronavirus pandemic.",2020-04-21 11:35:00-04:00,VCYT,negative
1307687.0,"The Daily Biotech Pulse: Moderna Secures $483M In BARDA Funding, Gilead Remdesivir Data, Veracyte's Positive Pre-Announcement",2020-04-17 07:35:00-04:00,VCYT,positive
1307688.0,Veracyte To Withdraw Full-Year FY20 Guidance,2020-04-16 16:34:00-04:00,VCYT,neutral
1307689.0,Veracyte Sees Q1 Prelim. Sales $30.5M-$31.5M Vs. $30.35M Est.,2020-04-16 16:33:00-04:00,VCYT,neutral
1307690.0,"The Daily Biotech Pulse: Pfizer's Eczema Drug Aces Latestage Study, Orphan Drug Designation For Dicerna, Dyadic's COVID-19 Connection",2020-03-19 07:37:00-04:00,VCYT,neutral
1307691.0,Stocks That Hit 52-Week Lows On Wednesday,2020-03-18 11:37:00-04:00,VCYT,negative
1307692.0,"The Daily Biotech Pulse: Roche Obtains FDA Emergency Use Authorization For COVID-19 Test, Chembio Appoints New CEO, Inovio Slumps On Earnings",2020-03-13 07:52:00-04:00,VCYT,negative
1307693.0,10 Biggest Price Target Changes For Wednesday,2020-02-26 08:45:00-05:00,VCYT,neutral
1307694.0,"Needham Maintains Buy on Veracyte, Lowers Price Target to $30",2020-02-26 06:45:00-05:00,VCYT,negative
1307695.0,Veracyte 8-K Shows Registration For Resale Of Up To ~376.7K Shares Of Common Stock To NanoString Technologies,2020-02-25 17:43:00-05:00,VCYT,positive
1307696.0,Veracyte Sees FY20 Sales $138M-$142M vs $136M Estimate,2020-02-25 16:12:00-05:00,VCYT,neutral
1307697.0,"Veracyte Q4 EPS $(0.15) Misses $(0.07) Estimate, Sales $29.73M Beat $29.53M Estimate",2020-02-25 16:12:00-05:00,VCYT,negative
1307698.0,"The Daily Biotech Pulse: Moderna Ships COVID-19 Vaccine For Clinics, Mallinckrodt Strikes $1.6B Opioid Settlement",2020-02-25 08:28:00-05:00,VCYT,negative
1307699.0,The Week Ahead In Biotech: Biopharma Earnings Pick Up Pace,2020-02-23 18:38:00-05:00,VCYT,neutral
1307700.0,Veracyte Announces Biopharmaceutical Collaboration With Acerta Pharma,2020-01-08 08:22:00-05:00,VCYT,neutral
1307701.0,"The Daily Biotech Pulse: Roche's Tecentriq Snags FDA Nod For Lung Cancer, Rapt Out-Licenses Cancer Drug",2019-12-04 07:06:00-05:00,VCYT,negative
1307702.0,"Nanostring Technologies Says on December 3, Co Entered Into a License & Asset Purchase Agreement With Veracyte; Co Granted to Veracyte Exclusive Worldwide License to Ncounter Flex Analysis System; Sold to Veracyte Certain Assets",2019-12-04 06:08:00-05:00,VCYT,positive
1307703.0,Veracyte Acquires Exclusive License to NanoString Diagnostics Platform For $40M In Cash And $10M In Stock; Co. Sees $6M-$8M Revenue Contribution In 2020,2019-12-03 17:03:00-05:00,VCYT,positive
1307704.0,Veracyte Announced New Data That Advance Understanding of Genomic Alterations Targeted by Precision Medicine Therapies for Thyroid Cancer,2019-11-03 12:53:00-05:00,VCYT,negative
1307705.0,Veracyte Highlights New Data Characterizing Genomic Alterations in Thyroid Cancer To Be Presented at 89th Annual Meeting of the American Thyroid Association,2019-10-30 08:16:00-04:00,VCYT,negative
1307706.0,41 Biggest Movers From Yesterday,2019-10-24 04:25:00-04:00,VCYT,neutral
1307707.0,"Veracyte Reaffirms FY19 Sales Guidance Of $119M-$122M, Operating Activities Net Cash Of $2M-$4M",2019-10-22 16:18:00-04:00,VCYT,neutral
1307708.0,"Veracyte Q3 EPS $(0.02) Beats $(0.07) Estimate, Sales $31M Beat $30.1M Estimate",2019-10-22 16:16:00-04:00,VCYT,neutral
1307709.0,"The Daily Biotech Pulse: Biogen Alzheimer's Program Back On Track, Novartis Reports Strong Quarter, Takeda In-Licenses Autoimmune Disorder Drug",2019-10-22 07:51:00-04:00,VCYT,positive
1307710.0,Veracyte Highlights New Clinical Data Showing First-Ever Noninvasive Nasal Swab Test Can Enable Early Lung Cancer Detection and Diagnosis,2019-10-22 07:08:00-04:00,VCYT,negative
1307711.0,Veracyte Highlights Data Showing Clinical Validity Of Next-Gen Percepta Classifier Will Be Presented At American College of Chest Physicians Thurs.,2019-10-21 16:16:00-04:00,VCYT,neutral
1307712.0,Veracyte Reports Data From 3 Studies Presented At American College of Chest Physicians Meeting Showing Envisia Improves Physicians' Ability To Diagnose Idiopathic Pulmonary Fibrosis,2019-10-21 09:58:00-04:00,VCYT,positive
1307713.0,"Veracyte Highlights Publication Of Clinical, Analytical Validation Data For Afirma Xpression Atlas",2019-09-11 11:05:00-04:00,VCYT,neutral
1307714.0,50 Stocks Moving In Tuesday's Mid-Day Session,2019-09-10 12:19:00-04:00,VCYT,neutral
1307715.0,Veracyte Highlights Publication Of New Study Characterizing Gene Alterations In Thyroid Cancer,2019-09-03 08:16:00-04:00,VCYT,negative
1307716.0,ï»¿Shares of several healthcare companies are trading higher with the overall market after the U.S. announced it is excluding and delaying the additional 10% tariff on certain products.,2019-08-13 11:53:00-04:00,VCYT,positive
1307717.0,"Benzinga's Top Upgrades, Downgrades For July 31, 2019",2019-07-31 10:02:00-04:00,VCYT,positive
1307718.0,Lake Street Initiates Coverage On Veracyte with Buy Rating,2019-07-31 09:13:00-04:00,VCYT,neutral
1307719.0,Veracyte Raises FY19 Sales Guidance From $117M-$121M To $119M-$122M vs $119.3M Estimate,2019-07-30 16:25:00-04:00,VCYT,neutral
1307720.0,"Veracyte Q2 EPS $(0.05) Beats $(0.1) Estimate, Sales $30.136M Beat $28.84M Estimate",2019-07-30 16:24:00-04:00,VCYT,neutral
1307721.0,"The Daily Biotech Pulse: European Cheer For Merck, Legal Victory For Coherus, Medpace Picks Up On Earnings",2019-07-30 07:00:00-04:00,VCYT,positive
1307722.0,"The Week Ahead In Biotech: Pending Clinical Readouts, Earnings Dominate",2019-07-27 14:32:00-04:00,VCYT,negative
1307723.0,60 Biggest Movers From Yesterday,2019-07-24 04:57:00-04:00,VCYT,neutral
1307724.0,45 Stocks Moving In Tuesday's Mid-Day Session,2019-07-23 13:09:00-04:00,VCYT,neutral
1307725.0,"The Daily Biotech Pulse: Acadia Schizophrenia Drug Fails, Viveve Plummets, Eisai Gets Breakthrough Therapy Designation",2019-07-23 07:26:00-04:00,VCYT,negative
1307726.0,"Benzinga's Top Upgrades, Downgrades For July 2, 2019",2019-07-02 09:13:00-04:00,VCYT,positive
1307727.0,"Needham Initiates Coverage On Veracyte with Buy Rating, Announces $33 Price Target",2019-07-02 06:56:00-04:00,VCYT,neutral
1307728.0,Veracyte Announces Keith Kennedy COO and CFO,2019-07-01 08:11:00-04:00,VCYT,neutral
1307729.0,Veracyte Reports Its Percepta Genomic Sequencing Classifer Now Available To Physicians,2019-06-26 16:23:00-04:00,VCYT,neutral
1307730.0,"The Daily Biotech Pulse: PhaseBio Pumped Up, Eiger Exults On Breakthrough Therapy Designation, Biohaven Slips On Stock Sale",2019-06-18 07:31:00-04:00,VCYT,neutral
1307731.0,Veracyte Announces New Article Published in Cancer Cytopathology Detailing Clinical Utility of Its RNA Sequencing-Based Testing for Thyroid Cancer Diagnosis and Treatment,2019-06-17 08:30:00-04:00,VCYT,negative
1307732.0,"The Daily Biotech Pulse: Lilly Reports Positive Long-Term Efficacy Data For Psoriasis Drug, Provention Bio Offering",2019-06-11 07:34:00-04:00,VCYT,positive
1307733.0,Veracyte Highlights Publication Of Data Showing 'Real-World Performance of the Afirma GSC in Thyroid Cancer Diagnosis',2019-06-10 16:16:00-04:00,VCYT,negative
1307734.0,Shares of several healthcare companies are trading higher with the overall US market. Recent comments out of China and Mexico has renewed trade optimism and lifted economic outlook.,2019-06-04 13:07:00-04:00,VCYT,positive
1307735.0,Veracyte Sat. Announced New Data Showing Potential of Afirma Genomic Test to Guide Targeted Treatment for Medullary Thyroid Cancer Concurrent with Diagnosis,2019-06-03 09:50:00-04:00,VCYT,negative
1307736.0,64 Biggest Movers From Friday,2019-06-03 06:12:00-04:00,VCYT,neutral
1307737.0,Veracyte Announces New Data Showing Potential of Afirma Genomic Test to Guide Targeted Treatment for Medullary Thyroid Cancer Concurrent with Diagnosis at #ASCO19,2019-06-01 15:23:00-04:00,VCYT,negative
1307738.0,Shares of many healthcare companies are trading lower following a tweet from President Trump late Thursday stating the US will impose a 5 percent tariff on goods from Mexico.,2019-05-31 10:25:00-04:00,VCYT,negative
1307739.0,Veracyte Highlights Will Present New Data Showing Afirma Xpression Atlas's Potential to Inform Treatment Selection for Patients with Medullary Thyroid Cancer At ASCO,2019-05-23 08:09:00-04:00,VCYT,negative
1307740.0,Veracyte Prices Public Offering of 5.5M Shares of Common Stock at $23.25/Share,2019-05-02 19:58:00-04:00,VCYT,positive
1307741.0,"The Daily Biotech Pulse: FDA Nod For Sanofi's Dengue Vaccine, Veracyte Offering, Biogen Reports Positive Data",2019-05-02 08:16:00-04:00,VCYT,positive
1307742.0,60 Biggest Movers From Yesterday,2019-05-02 06:10:00-04:00,VCYT,neutral
1307743.0,Veracyte Reports 5M Share Common Stock Offering,2019-05-01 17:59:00-04:00,VCYT,positive
1307744.0,46 Stocks Moving In Wednesday's Mid-Day Session,2019-05-01 13:24:00-04:00,VCYT,neutral
1307745.0,"Veracyte Reported Tues. AFternoon Q1 EPS $(0.05) Beats $(0.1) Estimate, Sales $29.529M Beat $27.61M Estimate",2019-05-01 10:34:00-04:00,VCYT,neutral
1307746.0,"The Daily Biotech Pulse: Nabriva Stumbles At FDA Hurdle, Gilead CFO To Retire, Eisai Ends Collaboration With Purdue",2019-05-01 07:39:00-04:00,VCYT,neutral
1307747.0,"The Daily Biotech Pulse: Earnings Deluge, G1 Therapeutics Positive FDA Meeting, Mustang Bio Offering",2019-04-30 08:06:00-04:00,VCYT,positive
1307748.0,"The Daily Biotech Pulse: FDA Accepts Alder's Migraine Drug Application, Gritstone Offering, Lilly's Chinese Sale",2019-04-23 08:08:00-04:00,VCYT,positive
1307749.0,Veracyte Reports Received Regulatory Authorization To Offer Envisia Genomic Classifer For Patients In State Of New York,2019-04-22 16:16:00-04:00,VCYT,neutral
1307750.0,Veracyte Announces Data Published in The Lancet Respiratory Medicine Demonstrate that the Envisia Genomic Classifier Improves Diagnosis of IPF,2019-04-02 05:52:00-04:00,VCYT,positive
1307751.0,"The Daily Biotech Pulse: Japanese Cheer For AbbVie, Myokardia Offering, CytomX CFO Departs",2019-03-26 07:36:00-04:00,VCYT,positive
1307752.0,Veracyte Highlights New Afirma Xpression Atlas Data Presented At ENDO 2019 Conference,2019-03-25 16:21:00-04:00,VCYT,neutral
1307753.0,"The Daily Biotech Pulse: Immutep Gets US Patent, Conatus NASH Disappointment, Eisai Moves On After Aducanumab Setback",2019-03-22 08:16:00-04:00,VCYT,negative
1307754.0,"The Daily Biotech Pulse: Biogen Plummets, FDA Greenlights Sleep Disorder Drug, Cellular Biomedicine Offering",2019-03-21 07:51:00-04:00,VCYT,negative
1307755.0,Veracyte To Present Afirma Xpression Atlas Data On Medullary Thyroid Cancer To Be Presented At ENDO 2019,2019-03-18 07:33:00-04:00,VCYT,negative
1307756.0,"Shares of several biotech companies are trading lower after FDA commissioner Scott Gottlieb announced he will resign; he pushed to spur the development of new drugs and with his absence, there is concern on future FDA approvals.",2019-03-06 11:59:00-05:00,VCYT,negative
1307757.0,Veracyte Receives Final Medicare Coverage Policy For Envisia Genomic Classifier,2019-03-04 16:26:00-05:00,VCYT,neutral
1307758.0,"The Daily Biotech Pulse: FDA Panel Vote Sinks KaryoPharm, Refuse-To-file Letter For Adamis, Tandem Diabetes Earnings",2019-02-27 08:13:00-05:00,VCYT,neutral
1307759.0,"The Daily Biotech Pulse: Immunomedics CEO Departs, Ultragenyx Offering, Karyopharm Awaits FDA Panel Vote",2019-02-26 07:56:00-05:00,VCYT,positive
1307760.0,"Veracyte Q4 EPS $(0.08) Beats $(0.15) Estimate, Sales $25.75M Beat $24.36M Estimate",2019-02-25 17:07:00-05:00,VCYT,neutral
1307761.0,Veracyte Q4 Earnings Preview,2019-02-25 10:52:00-05:00,VCYT,neutral
1307762.0,"The Week Ahead In Biotech: Conferences, PDUFA Dates, Clinical Trials, Earnings, IPOs",2019-02-22 13:55:00-05:00,VCYT,neutral
1307763.0,"The Daily Biotech Pulse: Gilead Earnings, Codexis Sings Pact With Merck, Eli Lilly Reports Positive Trial Results",2019-02-05 07:47:00-05:00,VCYT,positive
1307764.0,"The Daily Biotech Pulse: Merck Earnings, Positive Relaunch Of  Titan's Opioid Disorder Treatment Implant",2019-02-01 09:10:00-05:00,VCYT,positive
1307765.0,"The Daily Biotech Pulse: PTC Therapeutics, Select Biosciences Offering, Unity Biotech Expands Early-Stage Osteoarthritis Drug Study",2019-01-23 07:22:00-05:00,VCYT,positive
1307766.0,"Stocks Which Set New 52-Week High Yesterday, Thurs., Jan. 10, 2019",2019-01-11 13:04:00-05:00,VCYT,neutral
1307767.0,"The Daily Biotech Pulse: Agile Gives Regulatory Update On Contraceptive Patch, Advaxis Misses Estimates, Ocular Submits sNDA",2019-01-11 08:38:00-05:00,VCYT,negative
1307768.0,58 Biggest Movers From Yesterday,2019-01-04 05:35:00-05:00,VCYT,neutral
1307769.0,44 Stocks Moving In Thursday's Mid-Day Session,2019-01-03 12:27:00-05:00,VCYT,neutral
1307770.0,Veracyte shares are trading up after the company announced a strategic collaboration with J&J Innovation for lung cancer detection.,2019-01-03 11:00:00-05:00,VCYT,negative
1307771.0,"UPDATE: Veracyte Reports Will Combine Clinical Study Cohorts Involving 5K+ Patients, Multiple Years Of Clinical Outcome Data",2019-01-03 07:16:00-05:00,VCYT,neutral
1307772.0,Veracyte Reports Strategic Collaboration With J&J Innovation For Lung Cancer Detection,2019-01-03 07:15:00-05:00,VCYT,negative
1307773.0,"Benzinga's Top Upgrades, Downgrades For November 29, 2018",2018-11-29 09:00:00-05:00,VCYT,positive
1307774.0,Janney Capital Downgrades Veracyte to Neutral,2018-11-29 07:54:00-05:00,VCYT,neutral
1307775.0,70 Biggest Movers From Yesterday,2018-11-13 04:46:00-05:00,VCYT,neutral
1307776.0,54 Stocks Moving In Monday's Mid-Day Session,2018-11-12 12:38:00-05:00,VCYT,neutral
1307777.0,74 Biggest Movers From Friday,2018-11-05 04:36:00-05:00,VCYT,neutral
1307778.0,64 Stocks Moving In Friday's Mid-Day Session,2018-11-02 12:44:00-04:00,VCYT,neutral
1307779.0,"Stocks Which Set New 52-Week High Yesterday, October 31st",2018-11-01 10:33:00-04:00,VCYT,neutral
1307780.0,"The Daily Biotech Pulse: AbbVie's Leukemia Drug Trial Meets Endpoint, Denali Strikes Collaboration Deal",2018-11-01 07:30:00-04:00,VCYT,negative
1307781.0,82 Biggest Movers From Yesterday,2018-11-01 04:38:00-04:00,VCYT,neutral
1307782.0,66 Stocks Moving In Wednesday's Mid-Day Session,2018-10-31 12:50:00-04:00,VCYT,neutral
1307783.0,64 Biggest Movers From Yesterday,2018-10-31 05:00:00-04:00,VCYT,neutral
1307784.0,Mid-Afternoon Market Update: Crude Oil Down 1.8%; Veracyte Shares Jump After Q3 Results,2018-10-30 14:35:00-04:00,VCYT,negative
1307785.0,55 Stocks Moving In Tuesday's Mid-Day Session,2018-10-30 13:32:00-04:00,VCYT,neutral
1307786.0,Mid-Day Market Update: Dow Rises Over 200 Points; Electro Scientific Industries Shares Spike Higher,2018-10-30 12:54:00-04:00,VCYT,positive
1307787.0,Mid-Morning Market Update: Markets Open Higher; General Electric Misses Q3 Expectations,2018-10-30 10:46:00-04:00,VCYT,negative
1307788.0,"Veracyte Raises FY18 Sales Guidance From $87M-$89M To $90M-$91M vs $88.09M Est., Reduces Annual Cash Burn Guidance From $18M-$21M To $17M-$18M",2018-10-29 16:55:00-04:00,VCYT,neutral
1307789.0,"Veracyte Q3 EPS $(0.12) Beats $(0.25) Estimate, Sales $23.466M Beat $21.5M Estimate",2018-10-29 16:53:00-04:00,VCYT,neutral
1307790.0,Q3 Earnings Preview For Veracyte,2018-10-29 07:44:00-04:00,VCYT,neutral
1307791.0,"The Week Ahead In Biotech: Conferences, PDUFA Dates, Clinical Trial Results, Earnings And IPOs",2018-10-27 10:23:00-04:00,VCYT,neutral
1307792.0,"The Daily Biotech Pulse: Affimed's Cancer Drug Placed On Clinical Hold, Celgene's Positive Scalp Psoriasis Trial",2018-10-09 08:03:00-04:00,VCYT,negative
1307793.0,"Veracyte Announces New Data from Multiple Studies Demonstrate ""Real World"" Performance of Afirma GSC and Xpression Atlas in Thyroid Cancer Diagnosis",2018-10-07 07:32:00-04:00,VCYT,negative
1307794.0,Veracyte To Present New Data Highlighting The Ability Of Percepta Bronchial To Reduce Invasive Procedures At CHEST Annual Meeting,2018-09-27 08:16:00-04:00,VCYT,positive
1307795.0,"Stocks Which Set New 52-Week High Friday, August 31",2018-09-04 10:29:00-04:00,VCYT,neutral
1307796.0,"Stocks Which Set New 52-Week High Yesterday, August 30th",2018-08-31 10:11:00-04:00,VCYT,neutral
1307797.0,"The Daily Biotech Pulse: FDA Blessings for Merck's HIV Drug Combo, Veracyte's Test Gets Medicare Coverage",2018-08-31 08:29:00-04:00,VCYT,positive
1307798.0,UPDATE: Veracyte Says Received Draft Medicare Local Coverage Determination For Envisia Genomic Classifier Through MolDx Program,2018-08-30 16:08:00-04:00,VCYT,positive
1307799.0,Veracyte Highlights Medicare Milestone For Envisia Genomic Classifier,2018-08-30 16:07:00-04:00,VCYT,neutral
1307800.0,"Stocks Which Set New 52-Week High Friday, August 24th",2018-08-27 09:24:00-04:00,VCYT,neutral
1307801.0,"Stocks Which Set New 52-Week High Yesterday, August 16th",2018-08-17 10:39:00-04:00,VCYT,neutral
1307802.0,"Stocks Which Set New 52-Week High Yesterday, August 15th",2018-08-16 10:22:00-04:00,VCYT,neutral
1307803.0,"Stocks Which Set New 52-Week High Yesterday, August 9th",2018-08-10 10:03:00-04:00,VCYT,neutral
1307804.0,"The Daily Biotech Pulse: Puma, CareDx Soar On Earnings, Corcept Plunges On Bottom-Line Miss",2018-08-10 07:38:00-04:00,VCYT,negative
1307805.0,"Stocks Which Set New 52-Week Highs Friday, August 3rd",2018-08-06 13:02:00-04:00,VCYT,neutral
1307806.0,"Stocks Which Set New 52-Week High Yesterday, August 2nd",2018-08-03 11:16:00-04:00,VCYT,neutral
1307807.0,Veracyte Late Wednesday Announced Pricing Of 5M Share Common Stock Offering At $10.25/Share,2018-07-26 09:30:00-04:00,VCYT,positive
1307808.0,"Stocks Which Set New 52-Week High Yesterday, July 24th:",2018-07-25 12:14:00-04:00,VCYT,neutral
1307809.0,"Benzinga's Daily Biotech Pulse: Merck's Keytruda Found Effective, Nabriva To Acquire Zavante, FDA Denies Agile",2018-07-25 08:41:00-04:00,VCYT,positive
1307810.0,46 Biggest Movers From Yesterday,2018-07-25 04:03:00-04:00,VCYT,neutral
1307811.0,Veracyte Reports Offering Of 5M Common Shares,2018-07-24 16:02:00-04:00,VCYT,positive
1307812.0,34 Stocks Moving In Tuesday's Mid-Day Session,2018-07-24 12:28:00-04:00,VCYT,neutral
1307813.0,"Benzinga's Daily Biotech Pulse: Celgene's Lymphoma Trial Meets Endpoint, Merit Medical's Strong Q2, Bluebird Bio Offering",2018-07-24 08:53:00-04:00,VCYT,positive
1307814.0,Veracyte Raises FY18 Sales Outlook From $83M-$86M To $87M-$89M vs $84.54M Est.,2018-07-23 16:10:00-04:00,VCYT,neutral
1307815.0,Veracyte Raises FY18 Sales Guidance,2018-07-23 16:08:00-04:00,VCYT,neutral
1307816.0,"Veracyte Q2 EPS $(0.18) Beats $(0.27) Estimate, Sales $22.8M Beat $20.56M Estimate",2018-07-23 16:08:00-04:00,VCYT,neutral
1307817.0,Earnings Preview: Veracyte,2018-07-23 08:47:00-04:00,VCYT,neutral
1307818.0,"The Week Ahead In Biotech: Conferences, PDUFA Dates, Clinical Trial Results, Earnings And IPOs",2018-07-22 17:03:00-04:00,VCYT,neutral
1307819.0,"Benzinga's Daily Biotech Pulse: Acceleron On Fast Lane, OncoCyte's Accurate Diagnosis, Inspire Medical Gets Aetna Coverage",2018-07-10 08:11:00-04:00,VCYT,positive
1307820.0,"Benzinga's Daily Biotech Pulse: Realm Therapeutics To List On Nasdaq, CASI Pharma Added To Russell 2000 Index",2018-07-05 07:43:00-04:00,VCYT,neutral
1307821.0,Veracyte Highlights Clinical Validation Data Published In JAMA Surgery Showed Afirma Genomic Sequencing Classifier Identified At Least 1/3 More Benign Thyroid Nodules Among Those Deemed Indeterminate By Cytopathology,2018-05-23 11:23:00-04:00,VCYT,positive
1307822.0,UBS Global Healthcare Conference 2018 Concludes Today With Presenters Including Quidel and Veracyte,2018-05-23 07:02:00-04:00,VCYT,neutral
1307823.0,38 Biggest Movers From Yesterday,2018-05-23 04:56:00-04:00,VCYT,neutral
1307824.0,Veracyte Raises FY2018 Sales Guidance from $81.0M-83.0M to $83.0M-86.0M vs $89.80M Est,2018-05-01 17:02:00-04:00,VCYT,neutral
1307825.0,Veracyte Raises FY18 Sales Outlook,2018-05-01 17:01:00-04:00,VCYT,neutral
1307826.0,"Veracyte Q1 EPS $(0.27), Made $20.041M Sales",2018-05-01 17:01:00-04:00,VCYT,neutral
1307827.0,Veracyte S-3 Shows Registration For $125M Mixed Securities Shelf Offering,2018-05-01 16:58:00-04:00,VCYT,positive
1307828.0,"Veracyte Reports Precision Medicine Collab With Loxo Oncology, 'Leverages Veracyte's New Afirma Xpression Atlas Platform'",2018-04-11 08:11:00-04:00,VCYT,neutral
1307829.0,Veracyte To Unveil New Afirma Xpression Atlas Program At ENDO '18,2018-03-14 08:19:00-04:00,VCYT,neutral
1307830.0,Veracyte Sees FY18 Sales $81M-$83M vs $85M Est.,2018-02-27 16:01:00-05:00,VCYT,neutral
1307831.0,"Veracyte Reports Q4 EPS $(0.24) vs $(0.20) Est., Sales $19.596M vs $19M Est.",2018-02-27 16:01:00-05:00,VCYT,neutral
1307832.0,Veracyte Q4 Earnings Preview,2018-02-27 12:48:00-05:00,VCYT,neutral
1307833.0,UPDATE: Veracyte Says '61% endured an invasive procedure for diagnosis',2018-01-18 08:06:00-05:00,VCYT,neutral
1307834.0,Veracyte Reports Results Of Patient Survey Quantifying Challenges In Diagnosing Interstitial Lung Disease: '55% of participants in national Pulmonary Fibrosis Foundation survey reported at least one misdiagnosis',2018-01-18 08:05:00-05:00,VCYT,positive
1307835.0,"UPDATE: Veracyte Reports Will Consolidate Clinical, Medical, R&D Functions Into 1 Department",2018-01-08 07:39:00-05:00,VCYT,neutral
1307836.0,"Veracyte Company Reiterates 2017 Revenue Of $71-$72M and Cash Burn Guidance Of $25M to $26M, Announces Strategic Realignment and New Appointments to Advance Commercial Growth",2018-01-08 07:32:00-05:00,VCYT,positive
1307837.0,Veracyte Reports Publication of Data Confirming Analytical Validity of Envisia Genomic Classifier for Use in IPF Diagnosis,2017-11-28 08:30:00-05:00,VCYT,neutral
1307838.0,56 Biggest Movers From Yesterday,2017-11-08 04:40:00-05:00,VCYT,neutral
1307839.0,45 Stocks Moving In Tuesday's Mid-Day Session,2017-11-07 12:41:00-05:00,VCYT,neutral
1307840.0,"Veracyte Shares Resume Trade, Continue Lower, Now Down 23.7%",2017-11-07 09:35:00-05:00,VCYT,neutral
1307841.0,"Veracyte Shares Halted On Circuit Breaker, Down 20%; Stock To Resume Trade At 9:35:18 a.m. EST",2017-11-07 09:34:00-05:00,VCYT,positive
1307842.0,"Benzinga's Top Upgrades, Downgrades For November 7, 2017",2017-11-07 09:16:00-05:00,VCYT,positive
1307843.0,Janney Capital Downgrades Veracyte to Neutral,2017-11-07 07:58:00-05:00,VCYT,neutral
1307844.0,Veracyte Sees FY17 Sales $71-$72M vs $76M Est.,2017-11-06 16:07:00-05:00,VCYT,neutral
1307845.0,"Veracyte Reports Q3 EPS $(0.20) vs $(0.23) Est., Sales $17.5M vs $19.5M est.",2017-11-06 16:06:00-05:00,VCYT,neutral
1307846.0,UPDATE: Veracyte To Show 'Greater Than 50% Reduction in Patients [Using Percepta] Classified as Low Risk for Lung Cancer,2017-11-01 08:54:00-04:00,VCYT,negative
1307847.0,Veracyte Will Present New Clinical Utility Data At CHEST '17 Showing Percepta Classifier Reduces Invasive Procedures in Lung Cancer Diagnosis,2017-11-01 08:54:00-04:00,VCYT,negative
1307848.0,Veracyte Announces New Data Highlighting Performance of the Afirma GSC Ensemble Machine Learning Algorithms in Challenging Thyroid Cancer Subtypes to Be Presented at ATA Next-Generation Test is First to Distinguish Benign from Cancerous HÃ¼rthle Cells,2017-10-22 11:48:00-04:00,VCYT,negative
1307849.0,"Veracyte Reports Reimbursement Rate Fro Afirma Is Expected To Increase From $3,2020 To $3,600 For Calendar Year '18",2017-09-25 08:04:00-04:00,VCYT,positive
1307850.0,"BTIG Transitions Coverage Of Veracyte, Establishes Buy Rating And $13 Price Target",2017-08-31 07:38:00-04:00,VCYT,neutral
1307851.0,"Veracyte Reports Q2 EPS $(0.22) vs $(0.25) Est., Sales $18.4M vs $18.33M Est.",2017-07-31 16:10:00-04:00,VCYT,neutral
1307852.0,"UPDATE: Veracyte Says 'Enhanced Classifier Identifies 30% More Benign Patients Than Original, Flagship Test'",2017-07-31 08:42:00-04:00,VCYT,positive
1307853.0,Veracyte Reports Pivotal Clinical Validation Data For Afirma Genomic Sequencing Classifier,2017-07-31 08:42:00-04:00,VCYT,neutral
1307854.0,"Veracyte Reports Positive Data From 3 Afirma Studies to Be Presented at World Congress on Thyroid Cancer, Oral Presentation Highlights Next-Generation Afirma Genomic Sequencing Classifier",2017-07-26 08:36:00-04:00,VCYT,negative
1307855.0,"Veracyte Announces Clinical Data From Envisia Pivotal Study, Confirms Evisia's Ability To Detect UIP",2017-05-23 15:01:00-04:00,VCYT,positive
1307856.0,"Veracyte Reports Q1 EPS $(0.24) vs $(0.25) Est., Sales $16.432M vs $17.69M Est.",2017-05-03 17:45:00-04:00,VCYT,neutral
1307857.0,Veracyte Sees FY17 Sales $76M-$84M vs $80.3M Est.,2017-03-01 16:11:00-05:00,VCYT,neutral
1307858.0,"Veracyte Reports Q4 EPS $(0.14) vs $(0.26) Est., Sales $18.257M vs $17.5M Est.",2017-03-01 16:11:00-05:00,VCYT,neutral
1307859.0,Veracyte Reports Publication of Data Demonstrating Potential for Non-Invasive Nasal Test to Improve Lung Cancer Diagnosis,2017-02-27 10:21:00-05:00,VCYT,negative
1307860.0,Veracyte Afirma Now Considered Medically Appropriate By Blue Cross Blue Shield of Tennessee,2017-02-17 13:37:00-05:00,VCYT,neutral
1307861.0,25 Stocks Moving In Wednesday's Pre-Market Session,2017-02-08 08:28:00-05:00,VCYT,neutral
1307862.0,Veracyte Reports Will Extend Access to Its Afirma GEC Through Deal with Quest Diagnostics,2017-02-08 08:09:00-05:00,VCYT,positive
1307863.0,Veracyte's Percepta to be Covered by Medicare Administrative Contractor Palmetto,2017-02-06 08:09:00-05:00,VCYT,neutral
1307864.0,Benzinga's Top Upgrades,2016-11-29 08:49:00-05:00,VCYT,positive
1307865.0,Janney Capital Upgrades Veracyte to Buy,2016-11-29 08:03:00-05:00,VCYT,neutral
1307866.0,"Veracyte Says the Centers for Medicare and Medicaid Will Allow the Test Rate of $3,200 To Remain in 2017",2016-11-22 07:07:00-05:00,VCYT,positive
1307867.0,Veracyte Announces Keith Kennedy CFO,2016-11-21 08:03:00-05:00,VCYT,neutral
